scholarly journals Cytogenetic and Genetic Advances in Myelodysplasia Syndromes

2021 ◽  
Author(s):  
Mounia Bendari ◽  
Nisrine Khoubila
Keyword(s):  
Rna Splicing ◽  
Chromosomal Abnormalities ◽  
Single Nucleotide Polymorphism Array ◽  
Genetic Mutation ◽  
International Prognostic Scoring System ◽  
Trisomy 8 ◽  
Chromosome 5Q ◽  
Genomic Technologies ◽  
Genetic Abnormalities ◽  
Generation Sequencing

Myelodysplasia syndromes (MDS) are defined by a heterogeneous group of myeloid malignancies characterized by peripheral blood cytopenia and dishematopoiesis and frequently progress to acute myeloid leukemia. Conventional karyotype has a crucial role in myelodysplastic syndrome (MDS) and is one of items of the International Prognostic Scoring System (IPSS) for patient risk stratification and treatment selection. Approximately 50–60% of cases of MDS present chromosomal abnormalities, like the deletions of chromosome 5q and 7q, trisomy 8, and complex karyotypes. New genomic technologies have been developted, like single-nucleotide polymorphism array and next-generation sequencing. They can identify the heterozygous deletions wich result in haplo-insufficient gene expression (e.g., CSNK1A1, DDX41 on chromosome 5, CUX1, LUC7L2, EZH2 on chromosome 7) involved in the pathogenesis of myelodysplasia syndromes. Genetic abnormalities are multiple, the most recurrent one are involved in the RNA splicing like SF3B1, SRSF2, U2AF1, ZRSR2, LUC7L2, and DDX41. Epigenetic modifications are also identified, such as histone modification as ASXL1, EZH2. Finally, it can be DNA methylation (e.g., TET2, DNMT3A, IDH1/IDH2). On this review we will summarize the most recent progress in molecular pathogenesis of MDS, and try to better understand the pathogenesis of the specific subgroups of MDS patients and applications of discovery of new genetic mutation in the development of new therapeutic.

scholarly journals Coexistence of Recurrent Chromosomal Abnormalities and the Philadelphia Chromosome in Acute and Chronic Myeloid Leukemias: Report of Five Cases and Review of Literature

2020 ◽  
Author(s):  
Jinying Gong ◽  
Zhenhao Zhang ◽  
Wei Zhang ◽  
Huijun Wang ◽  
Xiaofang Feng ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chromosomal Abnormalities ◽  
Philadelphia Chromosome ◽  
Chromosomal Translocation ◽  
Myelogenous Leukemia ◽  
Trisomy 8 ◽  
Extra Copy ◽  
Genetic Abnormalities ◽  
Acute Myeloid

Abstract Progression of chronic myelogenous leukemia (CML) is frequently accompanied by cytogenetic evolution. Additional genetic abnormalities are seen in 10-20 % of CML cases at the time of diagnosis, and in 60–80 % of cases of advanced disease. Unbalanced chromosomal changes such as an extra copy of the Philadelphia chromosome (Ph), trisomy 8, and i(17)(q10) are common. Balanced chromosomal translocations, such as t(3;3), t(8;21), t(15;17), and inv(16) are typically found in acute myeloid leukemia, but rarely occur in CML. Translocations involving 11q23, t(8;21), and inv(16) are relatively common genetic abnormalities in acute leukemia, but are extremely rare in CML. In the literature to date, there are at least 76 Ph+ cases with t(3;21), 47 Ph+ cases with inv(16), 16 Ph+ cases with t(8;21), and 9 Ph+ cases with t(9;11). But most of what has been published is now over thirty years old, without the benefit of modern immunophenotyping to confirm diagnosis, and before the introduction of treatment regimes such as TKI. In this study, we explored the rare concomitant occurrence of coexistence current chromosomal translocation and t(9;22) in CML or acute myeloid leukemia (AML).

Incidence and Clinical Significance of Scoring System in Myelodysplastic Syndromes Including Hematological and Cytogenetic Profiles from a Single Institution

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5102-5102
Author(s):  
Myungshin Kim ◽  
Jihyang Lim ◽  
Yonggoo Kim ◽  
Kyungja Han ◽  
Yoo-Jin Kim ◽  
...  
Keyword(s):  
Scoring System ◽  
Who Classification ◽  
Chromosomal Abnormalities ◽  
Chromosome Analysis ◽  
World Health ◽  
International Prognostic Scoring System ◽  
Good Prediction ◽  
Trisomy 8 ◽  
Long Time ◽  
Health Organization

Abstract Background: Mydelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by hypercellular marrow with ineffective hematopoiesis determining peripheral cytopenia. Recently, the WHO developed a new classification that identifies the following subtypes: RA, RARS, 5q- syndrome (MDS 5q-), RCMD, RCMD with ringed sideroblasts (RCMDS), RAEB-1, RAEB-2 and MDS unclassifiable (MDS-U). The goals of our study were to establish the incidence of chromosome abnormalities in MDS patients, to correlate chromosomal defects with WHO subtype and peculiar clinical-biological findings. Patients and Methods: We studied 242 consecutive MDS patients who were admitted in the hematology department of St. Mary’s hospital from 2000 to 2007. The diagnosis was made according to the World Health Organization classification system. The chromosome analysis of the BM cells at diagnosis was performed by the G-staining method with trypsin and karyotyped according to the ISCN 2005. Results: The median age of patients was 50 (2–84). WHO classification was as follows: RA (n=21, 8.7%), RARS (n=7, 2.9%), RCMD (n=62, 25.6%), RCMDS (n=6, 2.5%), RAEB-1 (n=63, 26.0%), RAEB-2 (n=74, 30.6%), MDSU (n=7, 2.9%), MDS 5q- (n=2, 0.8%). Chromosomal abnormalities were found in 51.2% of patients. The cases with good, intermediate and poor cytogenetic risk features were observed in 55.0%, 29.3%, and 15.7%. Trisomy 8 was most common abnormality in all cases. 1q+, 5q-, 20q- were followed. By International Prognostic Scoring System (IPSS) 13 (5.4%) patients were classified in low group; 141 (58.3%) intermediate-1, 60 (24.8%) intermediate-2, and 28 (11.6%) high were classified. By WHO classification-based prognostic scoring system (WPSS), 14 (5.8%) patients were classified in very low group; 25 (10.3%) low, 57 (23.6%) intermediate, 110 (45.5%) high, and 36 (14.9%) very high were classified. Thirty-six patients (14.9%) progressed into AML. Both IPSS and WPSS was shown to predict survival and leukemia progression, even in a short-term prospective study (P<0.001). Conclusions: It is important to diagnose MDS accurately on the base of cytopenia, bone marrow morphology and clonal chromosomal abnormalities. IPSS and WPSS provide good prediction of survival and risk of leukemic evolution in MDS patients. The evaluation of clinical, hematological and cytogenetic analysis in more cases for long time follow-up will be helpful to standardize diagnosis of MDS.

scholarly journals Validation of a Next-Generation Sequencing Assay Targeting RNA for the Multiplexed Detection of Fusion Transcripts and Oncogenic Isoforms

2019 ◽  
Vol 144 (1) ◽  
pp. 90-98 ◽  
Author(s):  
Robyn T. Sussman ◽  
Amanda R. Oran ◽  
Carmela Paolillo ◽  
David Lieberman ◽  
Jennifer J. D. Morrissette ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Solid Tumors ◽  
Gold Standard ◽  
University Hospital ◽  
Fusion Partner ◽  
Next Generation ◽  
Fixed Tissue ◽  
Fusion Transcripts ◽  
Genetic Abnormalities ◽  
Generation Sequencing

Context.— Next-generation sequencing is a high-throughput method for detecting genetic abnormalities and providing prognostic and therapeutic information for patients with cancer. Oncogenic fusion transcripts are among the various classifications of genetic abnormalities present in tumors and are typically detected clinically with fluorescence in situ hybridization (FISH). However, FISH probes only exist for a limited number of targets, do not provide any information about fusion partners, cannot be multiplex, and have been shown to be limited in specificity for common targets such as ALK. Objective.— To validate an anchored multiplex polymerase chain reaction–based panel for the detection of fusion transcripts in a university hospital–based clinical molecular diagnostics laboratory. Design.— We used 109 unique clinical specimens to validate a custom panel targeting 104 exon boundaries from 17 genes involved in fusions in solid tumors. The panel can accept as little as 100 ng of total nucleic acid from PreservCyt-fixed tissue, and formalin-fixed, paraffin-embedded specimens with as little as 10% tumor nuclei. Results.— Using FISH as the gold standard, this assay has a sensitivity of 88.46% and a specificity of 95.83% for the detection of fusion transcripts involving ALK, RET, and ROS1 in lung adenocarcinomas. Using a validated next-generation sequencing assay as the orthogonal gold standard for the detection of EGFR variant III (EGFRvIII) in glioblastomas, the assay is 92.31% sensitive and 100% specific. Conclusions.— This multiplexed assay is tumor and fusion partner agnostic and will provide clinical utility in therapy selection for patients with solid tumors.

scholarly journals A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

2017 ◽  
Vol 19 (1) ◽  
pp. 99-106 ◽  
Author(s):  
Cristina Jiménez ◽  
María Jara-Acevedo ◽  
Luis A. Corchete ◽  
David Castillo ◽  
Gonzalo R. Ordóñez ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Next Generation Sequencing ◽  
Next Generation ◽  
Genetic Abnormalities ◽  
Sequencing Strategy ◽  
Generation Sequencing

scholarly journals ANALYSIS OF COMPLEX CHROMOSOMAL ABNORMALITIES IN A CASE OF MULTIPLE MYELOMA USING SPECTRAL KARYOTYPING

2018 ◽  
Vol 11 (9) ◽  
pp. 9
Author(s):  
Perumal Govindasamy ◽  
Pooja S Kulshreshtha ◽  
Prabu Pandurangan ◽  
Anil Tarigopula ◽  
Jayarama S Kadandale ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Chromosomal Abnormalities ◽  
Bone Marrow Cells ◽  
Spectral Karyotyping ◽  
Multicolor Fish ◽  
Genetic Abnormalities ◽  
Prognostic Outcome ◽  
Conventional Cytogenetics ◽  
Marrow Cells

Objective: It was proposed to determine the chromosomal abnormalities in a 49-year-old male patient with multiple myeloma (MM) employing both conventional and advanced molecular cytogenetic techniques.Methods: GTG-banding and spectral karyotyping (SKY) on fixed metaphases obtained from LPS-stimulated bone marrow cells and interphase fluorescence in situ hybridization (iFISH) on unsorted marrow cells were carried out to identify genetic markers of prognostic significance.Results: The abnormal chromosomes observed through conventional cytogenetics could be resolved with SKY technique. The translocation t(4;14) (p16;q32) indicating FGFR3/IGH fusion and deletion of 13q14.3 was noticed using iFISH. The genetic abnormalities confirmed a poor prognostic outcome in the patient who died within 6 months of diagnosis.Conclusion: This report emphasizes the need for multicolor FISH techniques besides iFISH to resolve complex abnormalities and to identify cryptic aberrations of importance in risk stratification of MM patients.

scholarly journals The genetic analysis of Chinese patients with clonal cytopenias using targeted next-generation sequencing

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Lijuan Zhang ◽  
YuYe Shi ◽  
Yue Chen ◽  
Shandong Tao ◽  
Wenting Shi ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Myelodysplastic Syndromes ◽  
Rna Splicing ◽  
Myeloproliferative Neoplasms ◽  
Chinese Patients ◽  
Newly Diagnosed ◽  
Next Generation ◽  
Targeted Next Generation Sequencing ◽  
Significant Difference ◽  
Generation Sequencing

Abstract Background Clonal hematopoiesis (CH) can be found in various myeloid neoplasms (MN), such as myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN), also in pre-MDS conditions. Methods Cytogenetics is an independent prognostic factor in MDS, and fluorescence in-situ hybridization (FISH) can be used as an adjunct to karyotype analysis. In the past 5 years, only 35 of 100 newly diagnosed MDS and MDS/MPN patients were identified abnormalities, who underwent the FISH panel. In addition, we examined a cohort of 51 cytopenic patients suspected MDS or MDS/MPN with a 20-gene next generation sequencing (NGS), including 35 newly diagnosed MN patients and 16 clonal cytopenias of undetermined significance (CCUS) patients. Results Compared with the CCUS group, the MN group had higher male ratio (22/13 vs 10/6), cytogenetics abnormalities rate (41.4% vs 21.4%) and frequency of a series of mutations, such as ASXL1 (28.6% vs 25%), U2AF1 (25.7% vs 25%), RUNX1 (20% vs 0.0%); also, higher adverse mutations proportion (75% vs 85.2%), and double or multiple mutations (54.3% vs 43.75%). There were 7 MN patients and 4 CCUS patients who experienced cardio-cerebrovascular embolism events demonstrated a significant difference between the two groups (25% vs 20%). Ten of the 11 patients had somatic mutations, half had DNA methylation, while the other half had RNA splicing. Additionally, six patients had disease transformation, and four patients had mutated U2AF1, including two CCUS cases and two MDS-EB cases. Following up to January 2021, there was no significant difference in over survival between the CCUS and MN groups. Conclusion NGS facilitates the diagnosis of unexplained cytopenias. The monitoring and management of CCUS is necessary, also cardio-cerebrovascular embolism events in patients with CH need attention in the clinical practice.

scholarly journals Study on clinical and genetic characteristics of male patients with non-obstructive azoospermia

2021 ◽  
Vol 141 (5) ◽  
pp. 39-45
Author(s):  
Nguyen Hoai Bac ◽  
Hoang Long
Keyword(s):  
Sex Chromosome ◽  
Chromosomal Abnormalities ◽  
Klinefelter Syndrome ◽  
Obstructive Azoospermia ◽  
Genetic Characteristics ◽  
Azfc Deletion ◽  
Genetic Abnormalities ◽  
History Of ◽  
Male Patients ◽  
Infertile Patients

We examined 501 patients with non - obstructive azoospermia to evaluate clinical, subclinical, and genetic characteristics. The results show that the average age of patients in the study was 29.8 ± 5.5 years. Primary infertility accounts for the majority, with a rate of 90.3%. There was 38.6% of patients had a history of mumps orchitis. The average levels of FSH, LH, testosterone were 31.6 ± 16.5 mIU/mL, 15.5 ± 10 mIU/mL and 12.8 ± 7.13 nmol/L, respectively. The prevalence of chromosomal abnormalities was 30.7%. Of these, the sex chromosome aneuploidy with 47,XXY karyotype (Klinefelter syndrome) accounted for 27.3%. The incidence of AZF microdeletion was 13.8%. Of these, AZFc deletion was the most common at the rate of 42.1%, AZFa deletion, which accounted for 2.6%, were the least prevalent, and the frequency of AZFd deletion was 5.3%. However, there was no solitary AZFb deletion, which combined with other AZF deletions with 34.2%. Our research shows that mumps orchitis and chromosomal abnormalities are the leading causes of azoospermia. Screening for genetic abnormalities plays an important role in infertile patients with non - obstructive azoospermia.

scholarly journals The possible significance of trisomy 8 in acute myeloid leukemia

2017 ◽  
Vol 5 (6) ◽  
pp. 2652 ◽  
Author(s):  
Salil N. Vaniawala ◽  
Monika V. Patel ◽  
Pratik D. Chavda ◽  
Shivangi H. Zaveri ◽  
Pankaj K. Gadhia
Keyword(s):  
Acute Myeloid Leukemia ◽  
Chromosomal Aberrations ◽  
Myeloid Leukemia ◽  
Chromosomal Abnormalities ◽  
Prognostic Significance ◽  
Chromosomal Translocation ◽  
Banding Technique ◽  
Trisomy 8 ◽  
Increased Risk ◽  
Acute Myeloid

Background: Acute myeloid leukemia (AML) is a heterogeneous disorder that results from a block in the differentiation of haematopoietic progenitor cells along with uncontrolled proliferation. Trisomy 8 is the most common recurring numerical chromosomal aberrations in acute myeloid leukemia (AML). It occurs either as a sole anomaly or together with other additional chromosomal aberrations. The prognostic significance of trisomy 8 in presence of other additional chromosomal abnormality depends on clonal cytogenetic changes. The patients with trisomy 8 had shorter survival with significantly increased risk with other chromosomal abnormality.Methods: Total 139 patients were screened between January 2016 to November 2016 who were suspected of AML cases. Bone marrow cultures were set up using conventional cytogenetic methods. Chromosomal preparation was made and subjected to GTG banding technique. Banded metaphases were analysed and karyotyped for further analysis.Results: Cytogenetic evaluation of karyotyped of 139 suspected AML patients showed 52 with t(8;21)(q22;q22), 36 with t(15;17)(q22;q12), and 11 with inv(16)(p13;q22). The rest 40 cases found with additional chromosomal abnormalities, of which 16 were sole trisomy 8 and 24 cases were found with other chromosomal abnormalities In addition, only one person found with t(8;21) and trisomy 8, while  three person having t(15;17) with trisomy 8.Conclusions: AML is considered to be one of the most important cytogenetic prognostic determinants. Recurrent chromosomal translocation with trisomy 8 varying 1.9% for t(8;21) and 8.3% for t(15;17). In the present study trisomy 8 in AML with known favourable anomalies is very small. Therefore, it cannot be taken as a prognostic marker.

Sign in / Sign up

Export Citation Format

Share Document